Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 8/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8772170 | 1.00 | LTB4R (0.48) | LTB4RSMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL8772152 | 0.88 | LTB4R (0.47) | LTB4RCYP4F2CYP4A11 | |
| SCHEMBL8772160 | 0.88 | LTB4R (0.47) | LTB4RCYP4F2CYP4A11 | |
| SCHEMBL16413141 | 0.80 | CYP4F2 (0.50) | SMN1; SMN2KDM4ENPC1RAB9ACYP4F2 | |
| SCHEMBL641761 | 0.75 | CYP4F2 (0.54) | SMN1; SMN2KDM4ENPC1RAB9ACYP4F2 | |
| SCHEMBL9431319 | 0.74 | CYP4F2 (0.52) | SMN1; SMN2KDM4ENPC1RAB9ACYP4F2 | |
| SCHEMBL4901644 | 0.74 | TP53 (0.50) | SMN1; SMN2KDM4ENPC1RAB9ATP53 | |
| SCHEMBL27974845 | 0.73 | CYP4F2 (0.55) | SMN1; SMN2KDM4ENPC1RAB9ACYP4F2 | |
| SCHEMBL8772253 | 0.72 | NOS1 (0.44) | LTB4R | |
| SCHEMBL8772241 | 0.72 | NOS1 (0.44) | LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0801061-A2 | Leucotrien-B4 derivatives, process for their preparation and their use as medicaments | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-10-15 | — | — | EP | disclosed |
| US-5614634-A | Leukotriene-B4 derivatives, process for their production and their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5440044-A | Leukotriene-B4 derivatives, process for their production and their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-08-08 | — | — | US | disclosed |
| EP-0477311-A1 | NEW LEUCOTRIENE B 4? DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-04-01 | — | — | EP | disclosed |
| WO-1991014676-A1 | NEW LEUCOTRIENE B4 DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1991-10-03 | — | — | WO | disclosed |